Compare Cassava Sciences Inc (FLNA) vs Gartner Inc (IT) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

Gartner (IT) trades at $195.09, up 5.02% today, showing strong momentum with three consecutive quarterly EPS beats. The stock exhibits bullish technical signals with support at $185 and resistance at $188. Fundamentally, the company maintains robust profitability with 69.63% gross margins and 12% net income margin, though 2025 net income declined to $729M from 2024's $1.3B. Recent news highlights AI advisory demand growth and the upcoming Gartner IT Symposium in October.

Outlook remains positive with analyst consensus at Buy (28%) and $174.63 price target, though current price exceeds target. Key opportunities include strong ROE (113.58%) and AI-driven consulting demand. Risks include negative cash flow trends (-$211M in 2025) and potential fiduciary investigation noted in recent filings. Institutional sentiment appears mixed with 56% Hold ratings.